z-logo
open-access-imgOpen Access
Anxiolytic Activity of SC-48274 Compared with Those of Buspirone and Diazepam in Experimental Anxiety Models
Author(s) -
Norio Ogawa,
Chiaki Hara,
Shunji Takaki
Publication year - 1993
Publication title -
japanese journal of pharmacology/japanese journal of pharmacology
Language(s) - English
Resource type - Journals
eISSN - 1347-3506
pISSN - 0021-5198
DOI - 10.1254/jjp.61.115
Subject(s) - buspirone , diazepam , anxiolytic , pharmacology , medicine , anxiety , anesthesia , psychology , receptor , agonist , psychiatry
The present study was performed to assess the anxiolytic activity of the novel anxiolytic SC-48274 in comparison with those of buspirone and diazepam. Drugs were administered p.o. The experimental anxiety models included gastric lesions of mice induced by socio-psychological stress in the communication box (CB) and the passive avoidance paradigm in rats. In the CB experiments, non-foot-shocked mice (responder) exposed to the emotional responses of foot-shocked mice (sender), 3 hr per day for 3 days, developed gastric lesions. Single treatments of diazepam (1, 2, 5 mg/kg) and SC-48274 (25, 50 mg/kg) prevented gastric lesion formation, but buspirone at 2.5-10 mg/kg did not. A 3-day treatment with SC-48274 at doses over 5 mg/kg prevented gastric lesions; and a 3-day treatment with buspirone at 2, 5 and 10 mg/kg prevented the lesions with a U-shaped dose-response. Diazepam also prevented gastric lesion formation at the doses of 1 and 2 mg/kg. In the passive avoidance response study, rats which had a single acquisition trial for 2 days were used. The step-down latency for rats to enter from the illuminated compartment to the dark one was recorded. Single treatments of SC-48274 (25 mg/kg), diazepam (5, 10 mg/kg) or buspirone (25 mg/kg) shortened the delayed latency. These results suggest that SC-48274 has anxiolytic activity of the same potency as buspirone and repeated-dose administration is needed to induce anxiolytic activity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here